Pretest: Trop-2 Antibody-Drug Conjugates for the Treatment of TNBC, HR+/HER2- BC, and NSCLC: Advancing Care in the Community Oncology Setting – 5.7.24 Webcast (ID: i889-11)

To assist us in evaluating the effectiveness of this activity, please complete the following pretest.
At the end of this survey, you will be redirected to the Zoom meeting.

Question Title

* 1. Contact Information:

Name:

Email:

Institution:

Question Title

* 2. Which of the following best describes your profession?

MD/DO

NP/APN

Other (please specify)

Question Title

* 3. Which of the following best describes your specialty?

Medical oncology

Hematology/oncology

Internal medicine

Other (please specify)

Question Title

* 4. Which of the following best describes your practice setting?

Academic-based

Community-based

Government/VA/DOD

Research

Other (please specify)

Question Title

* 5. How confident are you in the management of patients with breast cancer in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 6. How confident are you in the management of patients with NSCLC in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 7. Which of the following mechanisms is responsible for the high therapeutic index associated with TROP-2 ADCs?

Targeted cytotoxic effects on TROP2+ tumor cells only

Targeted cytotoxic effects on TROP2+ tumor cells as well as nonspecific destruction of neighboring TROP2+ tumor cells

Targeted cytotoxic effects on TROP2+ tumor cells as well as nonspecific destruction of neighboring TROP2+ and TROP2- tumor cells

Question Title

* 8. According to recently presented data from the TropICS-02 trial, treatment of HR+/HER2- mBC with sacituzumab govitecan improved overall survival by what percentage versus chemotherapy?

10 – 20%

20 – 30%

30 – 40%

Question Title

* 9. According to recent interim analysis of the TropION-Breast 01 trial, how does the risk for disease progression or death compare between patients with inoperable/metastatic HR-positive, HER2-low or negative treated with datopotamab deruxtecan versus those treated with chemotherapy?

The risk is 10% lower with chemotherapy

The risk is reduced by 20% with datopotamab deruxtecan

The risk is reduced by over 30% with datopotamab deruxtecan

The risk is similar with both treatments

Question Title

* 10. According to recent interim analysis of the TropION-Lung01 trial, how does the risk for disease progression or death compare between patients with locally advanced/metastatic NSCLC treated with datopotamab deruxtecan vs those treated with docetaxel?

The risk is reduced by 10% with docetaxel

The risk is reduced by 10% with datopotamab deruxtecan

The risk is reduced by 25% with datopotamab deruxtecan

The risk is similar with both treatments

Question Title

* 11. Nadia is a 50-year-old postmenopausal woman diagnosed with de novo metastatic HR+/HER2- BC (IHC 0) 3 years ago with metastases to the bones and liver. First-line treatment comprised aromatase inhibitor therapy and CDK 4/6 inhibitor. She progressed at 30 months. Second-line therapy is everolimus and fulvestrant, with rapid progression. She then receives capecitabine. She presents now with progression after 6 months. Which of the following later-line treatments would you choose?

HER-2-targeted ADC therapy

Trop-2 targeted ADC therapy

Systemic chemotherapy

PARP inhibitor therapy

Question Title

* 12. Based on current clinical trial evidence, which of the following describes a patient who would be a suitable candidate for treatment with a Trop-2 ADC?

Treatment-naive patient requiring neoadjuvant therapy for HER2+ BC

Patient with newly-diagnosed TROP2+ locally advanced NSCLC

Treatment-experienced patient with metastatic HR+/HER2-BC